Cargando…
Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809169/ https://www.ncbi.nlm.nih.gov/pubmed/27076751 http://dx.doi.org/10.4103/0973-1296.177912 |
_version_ | 1782423598613397504 |
---|---|
author | Shi, Zheng Yu, Tian Sun, Rong Wang, Shan Chen, Xiao-Qian Cheng, Li-Jia Liu, Rong |
author_facet | Shi, Zheng Yu, Tian Sun, Rong Wang, Shan Chen, Xiao-Qian Cheng, Li-Jia Liu, Rong |
author_sort | Shi, Zheng |
collection | PubMed |
description | BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight in the recent years as a promising new target for therapy of breast cancer. OBJECTIVE: Since virtual screening has become an integral part of the drug discovery process, it is of great significant to identify novel HER2 inhibitors by structure-based virtual screening. MATERIALS AND METHODS: In this study, we carried out a series of elegant bioinformatics approaches, such as virtual screening and molecular dynamics (MD) simulations to identify HER2 inhibitors from Food and Drug Administration-approved small molecule drug as potential “new use” drugs. Results: Molecular docking identified top 10 potential drugs which showed spectrum affinity to HER2. Moreover, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) might exert potential inhibitory effects against HER2-targeted anti-breast cancer therapeutics. CONCLUSION: Together, our findings may provide successful application of virtual screening studies in the lead discovery process, and suggest that our discovered small molecules could be effective HER2 inhibitor candidates for further study. SUMMARY: A series of elegant bioinformatics approaches, including virtual screening and molecular dynamics (MD) simulations were took advantage to identify human epidermal growth factor receptor-2 (HER2) inhibitors. Molecular docking recognized top 10 candidate compounds, which showed spectrum affinity to HER2. Further, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) in candidate compounds were identified as potential “new use” drugs against HER2-targeted anti-breast cancer therapeutics. Abbreviations used: HER2: Human epidermal growth factor receptor-2, FDA: Food and Drug Administration, PDB: Protein Database Bank, RMSDs: Root mean square deviations, SPC: Single point charge, PME: Particle mesh Ewald, NVT: Constant volume, NPT: Constant pressure, RMSF: Root-mean-square fluctuation. |
format | Online Article Text |
id | pubmed-4809169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-48091692016-04-13 Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening Shi, Zheng Yu, Tian Sun, Rong Wang, Shan Chen, Xiao-Qian Cheng, Li-Jia Liu, Rong Pharmacogn Mag Original Article BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight in the recent years as a promising new target for therapy of breast cancer. OBJECTIVE: Since virtual screening has become an integral part of the drug discovery process, it is of great significant to identify novel HER2 inhibitors by structure-based virtual screening. MATERIALS AND METHODS: In this study, we carried out a series of elegant bioinformatics approaches, such as virtual screening and molecular dynamics (MD) simulations to identify HER2 inhibitors from Food and Drug Administration-approved small molecule drug as potential “new use” drugs. Results: Molecular docking identified top 10 potential drugs which showed spectrum affinity to HER2. Moreover, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) might exert potential inhibitory effects against HER2-targeted anti-breast cancer therapeutics. CONCLUSION: Together, our findings may provide successful application of virtual screening studies in the lead discovery process, and suggest that our discovered small molecules could be effective HER2 inhibitor candidates for further study. SUMMARY: A series of elegant bioinformatics approaches, including virtual screening and molecular dynamics (MD) simulations were took advantage to identify human epidermal growth factor receptor-2 (HER2) inhibitors. Molecular docking recognized top 10 candidate compounds, which showed spectrum affinity to HER2. Further, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) in candidate compounds were identified as potential “new use” drugs against HER2-targeted anti-breast cancer therapeutics. Abbreviations used: HER2: Human epidermal growth factor receptor-2, FDA: Food and Drug Administration, PDB: Protein Database Bank, RMSDs: Root mean square deviations, SPC: Single point charge, PME: Particle mesh Ewald, NVT: Constant volume, NPT: Constant pressure, RMSF: Root-mean-square fluctuation. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4809169/ /pubmed/27076751 http://dx.doi.org/10.4103/0973-1296.177912 Text en Copyright: © Pharmacognosy Magazine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Shi, Zheng Yu, Tian Sun, Rong Wang, Shan Chen, Xiao-Qian Cheng, Li-Jia Liu, Rong Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title | Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title_full | Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title_fullStr | Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title_full_unstemmed | Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title_short | Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening |
title_sort | discovery of novel human epidermal growth factor receptor-2 inhibitors by structure-based virtual screening |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809169/ https://www.ncbi.nlm.nih.gov/pubmed/27076751 http://dx.doi.org/10.4103/0973-1296.177912 |
work_keys_str_mv | AT shizheng discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT yutian discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT sunrong discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT wangshan discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT chenxiaoqian discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT chenglijia discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening AT liurong discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening |